Table 1 Demographic, disease, and clinical trial characteristics of patients at time of enrollment by response group.

From: Sustained mucosal colonization and fecal metabolic dysfunction by Bacteroides associates with fecal microbial transplant failure in ulcerative colitis patients

 

Non-responder

(N = 9)

Responder

(N = 10)

P-value

Demographics

 Gender (% female)

44.4

30

0.86

 Age (mean year ± SD)

38.3 ± 10.4

43.0 ± 13.5

0.41

Clinical measures

 Biologic therapy (%)

33.3

40.0

1.00

 Steroid therapy (%)

22.2

20.0

1.00

 Years since diagnosis (mean ± SD)

8.78 ± 6.14

13.3 ± 12.1

0.32

 Extent of disease (left/right/transverse)

3/6/0

4/4/2

0.29

 Total mayo score (mean ± SD)

6.22 ± 1.39

5.90 ± 1.37

0.62

 Median ESR (min, max)

18 (5, 35)

7 (1, 45)

0.44

 Median CRP (min, max)

2.50 (1, 14)

2.75 (0.2, 54)

0.39

 Median fecal calprotectin (min, max)

993 (16, 2000)

182 (16, 751)

0.007

Clinical arms

 Antibiotic administration (Y/N)

6/3

4/6

0.37

 FMT delivery (C/E)

3/6

6/4

0.37

 Arm (Abx+,C/Abx−,C/Abx+,E/Abx−,E)

0/3/3/3

4/2/2/2

0.24

  1. Clinical response defined as a decrease ≥ 3 in Mayo score by the end of the clinical trial.
  2. ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; C, capsule; E, enema; Abx, antibiotics. Continuous variables were tested with a Wilcoxon rank sum test and categorical variables were tested using a Fisher’s exact test.
Back to article page